Lorlatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 50 mg,100 mg
Reference Brands: Lorbrena (USA)
Category:
Oncology Cancer Care
Lorlatinib is available in Tablets
and strengths such as 25 mg, 50 mg,100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Lorlatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Lorlatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lorlatinib, marketed under the brand names Lorbrena in the USA, Canada, and Japan, and Lorviqua in the European Union, is an oral anti-cancer medication used for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ALK-positive. As a targeted therapy, Lorlatinib works as an inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), enzymes that are involved in cancer cell growth and proliferation. By blocking these kinases, Lorlatinib slows tumor progression and helps manage advanced lung cancer in patients who have developed resistance to prior ALK-targeted therapies.
Administered orally as a tablet, Lorlatinib is designed to provide systemic exposure to inhibit tumor activity while maintaining a manageable safety profile. It is particularly valuable for patients with metastatic NSCLC where standard chemotherapy and earlier-generation ALK inhibitors have failed. Lorlatinib has demonstrated efficacy in crossing the blood-brain barrier, addressing central nervous system metastases commonly observed in ALK-positive NSCLC. Approved in multiple regulated markets, Lorlatinib represents a critical treatment option for patients with advanced lung cancer, offering targeted therapy for improved clinical outcomes and disease management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing